ArticleFrontiers in endocrinology2025
Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PD-1 inhibitors combined with tyrosine kinase inhibitor-associated hypothyroidism is a predictive factor for antitumor effectiveness in male patients with hepatocellular carcinoma.Oncology letters · 2026Article
- Predictive value of pre-existing thyroid autoantibodies for PD-1 inhibitor-induced hypothyroidism: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis.Frontiers in immunology · 2026Article
- Commentary: Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction.Frontiers in endocrinology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the correlation between thyroid immune-related adverse events (irAEs) and thyroid autoantibodies in cancer patients treated with immune checkpoint inhibitors (ICIs). Methods: A retrospective analysis was conducted on 316 cancer patients (139 females, 177 males; median age 64.0 [56.0-71.0] years) treated at Qingdao Chengyang District People's Hospital from January 2018 to December 2023. Patients were divided into a euthyroid group ( Results: Thyroid irAEs included subclinical thyrotoxicosis (19.94%, Conclusion: Patients with malignant tumors who had high levels of TPOAb and/or TRAb before treatment were more likely to develop thyroid immune-related adverse events (irAEs) after treatment. The importance of screening for baseline thyroid autoantibodies in predicting thyroid irAEs needs to be clearly understood, and close monitoring and notification to patients should be carried out, along with prior intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.